Cargando…

What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?

The prevalence of type 2 diabetes continues to increase, along with a proliferation of glucose-lowering treatment options. There is universal agreement in the clinical community for the use of metformin as the first-line glucose-lowering therapy for the majority of patients. However, controversy exi...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Marc, Morgan, Angharad R., Yousef, Zaheer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778564/
https://www.ncbi.nlm.nih.gov/pubmed/31410711
http://dx.doi.org/10.1007/s13300-019-00678-z